Search Results - "Olson, Juneko E Grilley"

Mature results of a prospective study of deintensified chemoradiotherapy for low‐risk human papillomavirus‐associated oropharyngeal squamous cell carcinoma by Chera, Bhishamjit S., Amdur, Robert J., Tepper, Joel E., Tan, Xianming, Weiss, Jared, Grilley‐Olson, Juneko E., Hayes, D. Neil, Zanation, Adam, Hackman, Trevor G., Patel, Samip, Sheets, Nathan, Weissler, Mark C., Mendenhall, William M.

“…BACKGROUND The purpose of the current study was to determine quality of life and tumor control from a prospective phase 2 clinical trial evaluating…”
Get full text

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial by Adkins, Douglas, Prof, Ley, Jessica, BS, Neupane, Prakash, MD, Worden, Francis, Prof, Sacco, Assuntina G, MD, Palka, Kevin, MD, Grilley-Olson, Juneko E, MD, Maggiore, Ronald, MD, Salama, Noha N, PhD, Trinkaus, Kathryn, PhD, Van Tine, Brian A, MD, Steuer, Conor E, MD, Saba, Nabil F, Prof, Oppelt, Peter, MD

“…SummaryBackgroundMost head and neck squamous-cell carcinomas (HNSCCs) are driven by p16 INK4A inactivation and cyclin D1 overexpression that results in…”
Get full text

Enhancing Next‐Generation Sequencing‐Guided Cancer Care Through Cognitive Computing by Patel, Nirali M., Michelini, Vanessa V., Snell, Jeff M., Balu, Saianand, Hoyle, Alan P., Parker, Joel S., Hayward, Michele C., Eberhard, David A., Salazar, Ashley H., McNeillie, Patrick, Xu, Jia, Huettner, Claudia S., Koyama, Takahiko, Utro, Filippo, Rhrissorrakrai, Kahn, Norel, Raquel, Bilal, Erhan, Royyuru, Ajay, Parida, Laxmi, Earp, H. Shelton, Grilley‐Olson, Juneko E., Hayes, D. Neil, Harvey, Stephen J., Sharpless, Norman E., Kim, William Y.

“…Background Using next‐generation sequencing (NGS) to guide cancer therapy has created challenges in analyzing and reporting large volumes of genomic data to…”
Get full text

Phase 2 trial of neoadjuvant chemotherapy and transoral endoscopic surgery with risk‐adapted adjuvant therapy for squamous cell carcinoma of the head and neck by Weiss, Jared M., Grilley‐Olson, Juneko E., Deal, Allison Mary, Zevallos, Jose P., Chera, Bhishamjit S., Paul, Jennifer, Knowles, Mary Fleming, Usenko, Dmitriy, Weissler, Mark C., Patel, Samip, Hayes, David N., Hackman, Trevor

“…BACKGROUND The objective of this study was to demonstrate the feasibility and efficacy of induction chemotherapy, surgery, and pathology‐guided adjuvant…”
Get full text

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors by Doz, François, van Tilburg, Cornelis M, Geoerger, Birgit, Højgaard, Martin, Øra, Ingrid, Boni, Valentina, Capra, Michael, Chisholm, Julia, Chung, Hyun Cheol, DuBois, Steven G, Gallego-Melcon, Soledad, Gerber, Nicolas U, Goto, Hiroaki, Grilley-Olson, Juneko E, Hansford, Jordan R, Hong, David S, Italiano, Antoine, Kang, Hyoung Jin, Nysom, Karsten, Thorwarth, Anne, Stefanowicz, Joanna, Tahara, Makoto, Ziegler, David S, Gavrilovic, Igor T, Norenberg, Ricarda, Dima, Laura, De La Cuesta, Esther, Laetsch, Theodore W, Drilon, Alexander, Perreault, Sebastien

“…Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK…”
Get full text

The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate‐risk HPV‐negative HNSCC by Tasoulas, Jason, Lenze, Nicholas R., Farquhar, Douglas, Schrank, Travis, Shen, Colette, Shazib, M. Ali, Singer, Bart, Patel, Shetal, Grilley Olson, Juneko E., Hayes, David N., Gulley, Margaret L., Chera, Bhishamjit S., Hackman, Trevor, Olshan, Andrew F., Weiss, Jared, Sheth, Siddharth

“…Background Only high‐risk tumors with extranodal extension (ENE) and/or positive surgical margins (PSM) benefit from adjuvant therapy (AT) with concurrent…”
Get full text

A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma by Chawla, Sant P, Goel, Sanjay, Chow, Warren, Braiteh, Fadi, Singh, Arun S, Olson, Juneko E Grilley, Osada, Atsushi, Bobe, Iulian, Riedel, Richard F

“…NC-6300 is a novel nanoparticle formulation of epirubicin that has a pH-sensitive linker conjugated to epirubicin. It exhibits selective tumor accumulation…”
Get full text

Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate‐risk and high‐risk head and neck squamous cell carcinoma by Chera, Bhishamjit S., Sheth, Siddharth H., Patel, Shetal A., Goldin, Dan, Douglas, Kathe E., Green, Rebecca L., Shen, Colette J., Gupta, Gaorav P., Moore, Dominic T., Grilley Olson, Juneko E., Weiss, Jared M.

“…Background Adavosertib (AZD1775) is an inhibitor of the Wee1 kinase. The authors conducted a phase 1b trial to evaluate the safety of adavosertib in…”
Get full text

Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays by Coombs, Catherine C, Gillis, Nancy K, Tan, Xianming, Berg, Jonathan S, Ball, Markus, Balasis, Maria E, Montgomery, Nathan D, Bolton, Kelly L, Parker, Joel S, Mesa, Tania E, Yoder, Sean J, Hayward, Michele C, Patel, Nirali M, Richards, Kristy L, Walko, Christine M, Knepper, Todd C, Soper, John T, Weiss, Jared, Grilley-Olson, Juneko E, Kim, William Y, Earp, 3rd, H Shelton, Levine, Ross L, Papaemmanuil, Elli, Zehir, Ahmet, Hayes, D Neil, Padron, Eric

“…In this era of precision-based medicine, for optimal patient care, results reported from commercial next-generation sequencing (NGS) assays should adequately…”
Get full text

Sinonasal Squamous Cell Carcinoma Survival Outcomes Following Induction Chemotherapy vs Standard of Care Therapy by Murr, Alexander T., Lenze, Nicholas R., Weiss, Jared M., Grilley-Olson, Juneko E., Patel, Shetal A., Shen, Colette, Chera, Bhishamjit S., Zanation, Adam M., Thorp, Brian D., Sheth, Siddharth H.

“…Objective To compare oncologic outcomes in sinonasal squamous cell carcinoma (SNSCC) treated with standard of care (SOC) definitive therapy, consisting of…”
Get full text

Use of mobile device technology to continuously collect patient-reported symptoms during radiation therapy for head and neck cancer: A prospective feasibility study by Falchook, Aaron D., MD, Tracton, Gregg, BS, Stravers, Lori, MPH, CHES, Fleming, Mary E., ANP, Snavely, Anna C., PhD, Noe, Jeanne F., PharmD, Hayes, David N., MD, MPH, Grilley-Olson, Juneko E., MD, Weiss, Jared M., MD, Reeve, Bryce B., PhD, Basch, Ethan M., MD, Chera, Bhishamjit S., MD

“…Abstract Purpose Accurate assessment of toxicity allows for timely delivery of supportive measures during radiation therapy for head and neck cancer. The…”
Get full text

Concurrent Definitive Immunoradiotherapy for Patients with Stage III-IV Head and Neck Cancer and Cisplatin Contraindication by Weiss, Jared, Sheth, Siddharth, Deal, Allison M, Grilley Olson, Juneko E, Patel, Samip, Hackman, Trevor G, Blumberg, Jeffrey M, Galloway, Thomas J, Patel, Shetal, Zanation, Adam M, Shen, Colette J, Hayes, D Neil, Hilliard, Christopher, Mehra, Ranee, McKinnon, Karen P, Wang, Hsing-Hui, Weissler, Mark Christian, Bauman, Jessica R, Chera, Bhishamjit S, Vincent, Benjamin G

“…Although cisplatin plus radiotherapy is a standard treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC), cisplatin contraindication…”
Get full text

A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer by Volovat, Simona Ruxandra, Ciuleanu, Tudor-Eliade, Koralewski, Piotr, Olson, Juneko E. Grilley, Croitoru, Adina, Koynov, Krassimir, Stabile, Stefano, Cerea, Giulio, Osada, Atsushi, Bobe, Iulian, Volovat, Constantin

“…NC-6004 is a nanoparticle developed using micellar technology that can improve release of cisplatin, a standard treatment for many cancer types, and achieve…”
Get full text

A Randomized Phase II Study of Carboplatin With Weekly or Every‐3‐Week Nanoparticle Albumin‐Bound Paclitaxel (Abraxane) in Patients With Extensive‐Stage Small Cell Lung Cancer by Grilley‐Olson, Juneko E., Keedy, Vicki L., Sandler, Alan, Moore, Dominic T., Socinski, Mark A., Stinchcombe, Thomas E.

“…Background. Platinum plus etoposide is the standard therapy for extensive‐stage small cell lung cancer (ES‐SCLC) and is associated with significant…”
Get full text

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas by Coveler, Andrew L, Smith, David C, Phillips, Tycel, Curti, Brendan D, Goel, Sanjay, Mehta, Amitkumar N, Kuzel, Timothy M, Markovic, Svetomir N, Rixe, Olivier, Bajor, David L, Gajewski, Thomas F, Gutierrez, Martin, Lee, Hun Ju, Gopal, Ajay K, Caimi, Paolo, Heath, Elisabeth I, Thompson, John A, Ansari, Sahar, Jacquemont, Celine, Topletz-Erickson, Ariel, Zhou, Peigen, Schmitt, Michael W, Grilley-Olson, Juneko E

“…BackgroundSEA-CD40 is an investigational, non-fucosylated, humanized monoclonal IgG1 antibody that activates CD40, an immune-activating tumor necrosis factor…”
Get full text

Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors by Subbiah, Vivek, Grilley-Olson, Juneko E, Combest, Austin J, Sharma, Neelesh, Tran, Richard H, Bobe, Iulian, Osada, Atsushi, Takahashi, Kazuhiro, Balkissoon, Jaikrishna, Camp, Aaron, Masada, Atsuhiro, Reitsma, Dirk J, Bazhenova, Lyudmila A

“…NC-6004, a novel cisplatin nanoparticle developed using micellar technology exhibits sustained release of cisplatin and selective distribution to tumors…”
Get full text

Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer by Chera, Bhishamjit S, Kumar, Sunil, Beaty, Brian T, Marron, David, Jefferys, Stuart, Green, Rebecca, Goldman, Emily C, Amdur, Robert, Sheets, Nathan, Dagan, Roi, Hayes, D Neil, Weiss, Jared, Grilley-Olson, Juneko E, Zanation, Adam, Hackman, Trevor, Blumberg, Jeffrey M, Patel, Samip, Weissler, Mark, Tan, Xianming M, Parker, Joel S, Mendenhall, William, Gupta, Gaorav P

“…To identify a profile of circulating tumor human papilloma virus (HPV) DNA (ctHPVDNA) clearance kinetics that is associated with disease control after…”
Get full text

Interdigitating dendritic cell sarcoma of the supraglottic larynx by Sud, Shivani, Holmes, Jordan, Hackman, Trevor, Grilley-Olson, Juneko E, Chera, Bhisham

“…Abstract Background Interdigitating dendritic cell sarcoma (IDCS) is an extremely rare neoplasm with sparse published literature, limited to case reports. This…”
Get full text

A League of Its Own? Established and Emerging Therapies in Undifferentiated Pleomorphic Sarcoma by Graves, Laurie, Jeck, William R., Grilley-Olson, Juneko E.

“…Opinion statement Over the last decade in soft tissue sarcoma (STS) research, the shifting landscape towards more precise subtype classification and the…”
Get full text

Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers by Le, Xiuning, Baik, Christina, Bauman, Jessica, Gilbert, Jill, Brose, Marcia S, Grilley-Olson, Juneko E, Patil, Tejas, McDermott, Ray, Raez, Luis E, Johnson, Jennifer M, Shen, Lin, Tahara, Makoto, Ho, Alan L, Norenberg, Ricarda, Dima, Laura, Brega, Nicoletta, Drilon, Alexander, Hong, David S

“…Larotrectinib is a first-in-class, highly selective, and central nervous system-active tropomyosin receptor kinase (TRK) inhibitor approved for the treatment…”
Get full text